Delcath Systems, Inc. (NASDAQ:DCTH)

Delcath's little rebound last week might have seemed mystifying to those unfamiliar with zombie biotechs, but it's nothing I haven't seen a hundred times before. After a splatterfest like the 16-0 Ad Comm vote against Melblez, most of the investors and traders and speculators who guessed wrong and got their asses handed to them sell the shares and don't look back. The selling pressure often drives the stock below cash value, which is what happened with Delcath. At that point, bottom feeders start paying attention as the cash cushion allows time and elbow room for manipulation to make a quick profit.

Delcath bottomed at 0.38 on June 7, which gave them a market cap of 28M and cash of 43M thanks to heavy ATM dilution in the first quarter. Now, Delcath's prospects are certainly dismal but that won't prevent pumpers from predicting strong European sales of Chemosat and issuing optimistic predictions for the upcoming pivotal trial of Melblez in hepatocellular carcinoma. Nothing good is going to happen here in the long run, but Delcath is taking the stealth dilution route of a company that isn't prepared to die. 0.50 might not hold, but I wouldn't be averse to throwing in some spec money to ride a pump if the stub revisits 0.40.

Will pass FDA..

Delcath Systems has developed a method of delivering very high doses of chemotherapy to cancer-infested livers, while minimizing the toxicity to the rest of the patient. It's a great concept, but the bottom line is IT KEEPS PEOPLE ALIVE longer than conventional chemo does.

Right now, all eyes are on the pending FDA approval, and despite the fact that the system has already been approved in Europe, the FDA is the FDA. I believe they will do the right thing here, but you never know.

This stock will continue to grow will the anticipation of FDA approval.

PDUFA-date of June 14th. Run-up expected in May-2013. Expect run-up to $3.5+

Awaiting FDA answer to drug application in June, approx. 2 billion dollar market here in US alone for treatment of liver cancer. Already approved in Europe and Australia....what's not to love?

Technical play

upside potential unlimited when product benefits so many people and company is beaten down by the large drug companies. Delcath will be bought out by bms or pfizer in the near future

outperform

Cannot remember who I was following on this pick.

Mark4124NH

The PHP system they are developing will pass FDA approval and become the standard of care for organ chemotherapy treatment.

DCTH has a lot of cash for a development stage company. And unlike the run up in december to almost $12 per the NDA , this year they have exposure in Europe... could we then see a run up to $15-$16 before the next NDA in Sept 2011?? Something to think about...

Because the FDA did not squash the product but has unresolved questions about it that require clarification.

Great tecnology

DCTH is awaiting NDA from the FDA. It has begun to run as a result and its chart looks extremely positive technically. They just disclosed a 5.08% Blackrock stake in FDA 13g filing. And if the CEO is correct with his believe of 15b market potential, this stock is worth many times its current value.

FDA approval very optimistic.

Delcath should get approval for melanoma mid-2011. The opportunity is much bigger for its PHP system though.

This is really a no brainer when you get past all of the rhetoric. They built a system that puts Chemo only into the organ/region with cancer instead of poisoning the whole patient.

Once approved by the FDA in 2011 I predict a $50 share price.